2030 Clinical Research Therapies 
Drug Target Review
SEPTEMBER 22, 2023
Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. billion by 2030. Organoids for cell therapy and drug discovery. Cell Stem Cell [Internet]. 2023 May;30(5):571–91. Elsevier; 2020.
Vial
MAY 20, 2024
Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. What is a Pre-Clinical CRO? between 2024 and 2030. over this period.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PPD
OCTOBER 18, 2023
There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care. Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030.
The Pharma Data
SEPTEMBER 28, 2020
Developing next-generation therapies. Assessing an innovative therapy for patients with Chagas cardiomyopathy. Against this background, Novartis is pursuing an end-to-end approach, with activity on three fronts: drug discovery, clinical research and healthcare system strengthening. Follow us on social media.
Vial
FEBRUARY 8, 2024
To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials. billion in 2030. As von Itzstein et al.
Vial
APRIL 18, 2024
The urgency for novel therapeutic approaches makes ophthalmology a rapidly growing domain of clinical research. Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. from 2023 to 2030.
PPD
JANUARY 21, 2025
To better understand current challenges and their impact, the PPD clinical research business of Thermo Fisher Scientific surveyed global drug developers on the current state of the industry. This is especially critical in managing complex therapies, where precision and safety are paramount.
Expert insights. Personalized for you.
116 
Let's personalize your content